Table 1.
Baseline features of the metastatic melanoma population treated with checkpoint inhibitors.
| Feature | % (n = 68) |
|---|---|
| Age | |
| Median (interquartile range) years | 65 (34–85) |
| Sex | |
| Female | 43 (29) |
| Male | 57 (39) |
| Type of melanoma | |
| Cutaneous | 79 (54) |
| Mucosal | 3 (2) |
| Uveal | 4 (3) |
| Unknown origin | 14 (9) |
| BRAF V600 mutation | 53 (36) |
| NRAS Q61 mutation | 10 (7) |
| TNM stage at diagnosis | |
| II | 44 (30) |
| III | 38 (26) |
| IV | 18 (12) |
| Median Disease Free Survival (months) | 19 (0–144) |
| M stage | |
| M1a | 21 (14) |
| M1b | 14 (10) |
| M1c | 47 (32) |
| M1d | 18 (12) |
| Number of metastatic sites | |
| < 3 | 41 (28) |
| ≥3 | 59 (40) |
| ECOG | |
| 0 | 31 (21) |
| 1 | 48 (33) |
| 2 | 21 (14) |
| LDH | |
| <ULN * | 47 (32) |
| ≥ULN | 53 (36) |
| Line of systemic treatment | |
| Ipilimumab cohort | |
| As first line | 40 (19) |
| As second line | 60 (29) |
| PD1 inhibitors cohort | |
| As second line | 50 (10) |
| As third line | 50 (10) |
* ULN: Upper Limit of Normal.